Navigation Links
Wound Management Technologies Names Robert Lutz, Jr. as New CEO; Buys Back North American Distribution Rights for CellerateRX® Powder
Date:3/22/2012

FORT WORTH, Texas, March 22, 2012 /PRNewswire/ -- The Board of Directors of Wound Management Technologies, Inc., (OTCQB: WNDM | WNDM.PK) a leading innovator in advanced wound care solutions, announced today that Robert Lutz, Jr. has been appointed to the Board of Directors of the Company.  In addition, Scott A. Haire has resigned as Chairman of the Board of Directors and as Chief Executive Officer of the Company, and Deborah Jenkins Hutchinson has resigned as President of the Company, and Mr. Lutz has been elected as the new Chairman of the Board, Chief Executive Officer and President of the Company.  Mr. Haire and Ms Jenkins Hutchinson will continue on as directors of the Company.

Mr. Lutz has extensive management and leadership experience with both public and private companies, including subsidiaries of Liberty Corp, American Express and AMRESCO.  Mr. Lutz brings a proven track record in significantly growing the revenue and net income of companies, and has significant experience in negotiating business contracts with Fortune 100 firms, including IBM and AT&T. 

In conjunction with Mr. Lutz joining Wound Management, the Company has reacquired the North American distribution rights for its CellerateRX® advanced wound care powder from Juventas, LLC.  By doing so, Wound Management will be able to create a unified sales and distribution program for CellerateRX and its other products.  This reacquisition includes the acquisition of a newly-packaged specialized CellerateRX powder kit for use in the biologic surgical closure market that was successfully established by Juventas.  As a result, the management agreement between Wound Management and Juventas previously announced in November 2011 has also been terminated, and Juventas is no longer involved with Wound Management.

"After extensive due diligence with Wound Management and its core subsidiary, Wound Care Innovations, LLC, I am very impressed with the CellerateRX wound care products line and I believe the Company can capture a significant market share in the worldwide wound care products market," said Mr. Lutz.  "In addition to their current product lines, Wound Management has other significant opportunities with its Resorbable Orthopedic Products subsidiary to explore. I plan to announce a comprehensive strategic plan in the near future that will discuss these ideas, as well as other strategic initiatives I plan to introduce to the company."

"Bob's strong leadership, exceptional strategic vision, and past corporate performance will allow Wound Management to capitalize on its opportunities in the medical marketplace, while building shareholder value," said Mr. Haire. "I, along with other majority shareholders, support and welcome Bob to lead the Company forward."  Mr. Haire will remain as a major shareholder of Wound Management and will continue to assist the company in its strategic direction and future growth.

About Wound Management Technologies, Inc.

Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management's primary focus is the distribution of its unique, patented collagen product, CellerateRX®, which is FDA cleared and reimbursable under Medicare Part B. Wound Management has other advanced biotech products in development including a patented resorbable bone wax line that is in late stages of development, as well as a subsidiary focused on technology for secure healthcare data collaboration and storage.  More information can be found on the company's web sites: http://www.wmgtech.com and http://www.celleraterx.com.

Safe Harbor Statement:

The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

For Wound Management Technologies Shareholder Information please call (917) 974-9872 or visit http://www.wmgtech.com 

For Further Information:
Shareholder Relations-Communications (917) 974-9872


'/>"/>
SOURCE Wound Management Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Derma Sciences to Enter Phase II Development of Wound Healing Product That May Use Bodys Own Naturally Occurring Stem Cells
2. Aung FootHealth Clinics & Advanced Wound Care Center Enrolling Patients With Chronic Diabetic Foot Ulcers for Matrix Clinical Trial
3. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
4. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
5. Dr. Christopher Moore to Form ProDerm LP to Fund CVBT Wound Healing Trial
6. Wound Management Technologies, Inc. Announces Evidence Based Study
7. Wound Management Technologies, Inc. Announces Agreement for Evidence Based Study for Diabetic Venous Ulcers
8. Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing
9. Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)
10. New Study Using Combination of Bioengineered Skin and Stem Cells Shows Promise in Treatment of Non-Healing Wounds
11. Glycotex Investigational Compound GLYC-101 Achieves Accelerated Wound Closure Based on Interim Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... BRENTWOOD, Tenn. , March 1, 2017  Numotion, ... has announced the availability of Tek RMD ("robotic mobilization ... States . Tek RMD is a motorized standing ... are in a manual wheelchair to complete everyday activities ... board and control a Tek RMD unassisted. Numotion is ...
(Date:3/1/2017)... ... Research and Markets has announced the addition of the ... The Global Infertility Therapy Partnering Terms and Agreements ... agreements entered into by the world,s leading healthcare companies. ... deals are discovery or development stage whereby the licensee obtains a ...
(Date:3/1/2017)... MUMBAI, India and PRINCETON, ... Pharmaceutical Industries Ltd (Reuters: SUN.BO, Bloomberg: SUNP IN, ... its subsidiaries or associate companies) today announced that ... Phase-3 clinical trials (reSURFACE 1 and 2) of ... the treatment of moderate-to-severe plaque psoriasis, will be ...
Breaking Medicine Technology:
(Date:3/1/2017)... ... , ... Breast Surgeon, Dr. Dennis Holmes of 90210 Surgery Medical Center will ... it fits in the treatment paradigm at Susan G. Komen San Diego’s Annual Dinner ... leading cancer and wellness experts to share the latest innovations in breast cancer research, ...
(Date:3/1/2017)... ... 2017 , ... Award-winning medical group Allied Anesthesia today announced that, as of ... averaging more than one trip per year since 1998. Char was named the Los ... the details of his charitable work. Char has been an Allied Anesthesiologist since 2000. ...
(Date:3/1/2017)... (PRWEB) , ... March 01, 2017 , ... ... pledge to help increase colorectal cancer screening rates by supporting the 80% by ... Control and Prevention (CDC) and the National Colorectal Cancer Roundtable (an organization co-founded ...
(Date:3/1/2017)... ... March 01, 2017 , ... March 2017 – All year ... people don’t want to stop training to brave the cold weather, snow or ice. ... a small incline can help protect these vulnerable joints, says orthopaedic surgeon Kevin D. ...
(Date:3/1/2017)... , ... March 01, 2017 , ... “There is Comfort ... she gave to the author in their all-too-brief time together, and the soul-healing comfort ... the Soul” is the creation of published author, Jerie A. Tau, a dog-loving medical ...
Breaking Medicine News(10 mins):